6-methyl-N-(pyridin-2-yl)pyridine-2-carboxamide | 99989-03-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-methyl-N-(pyridin-2-yl)pyridine-2-carboxamide
• 英文别名: 6-methyl-pyridine-2-carboxylic acid-[2]pyridylamide；6-Methyl-pyridin-2-carbonsaeure-[2]pyridylamid；6-methyl-N-pyridin-2-yl-pyridine-2-carboxamide；6-methyl-N-(pyridin-2-yl)picolinamide；6-methyl-N-pyridin-2-ylpyridine-2-carboxamide
• CAS: 99989-03-4
• 化学式: C₁₂H₁₁N₃O
• mdl: MFCD13394468
• 分子量: 213.239
• InChiKey: UUYBLNWVKXRGHB-UHFFFAOYSA-N

物化性质

• 沸点：
  153 °C(Press: 0.35 Torr)
• 密度：
  1.246±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.083
• 拓扑面积：
  54.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-氨基吡啶 、 乙基 6-甲基吡啶-2-羧酸酯 生成 6-methyl-N-(pyridin-2-yl)pyridine-2-carboxamide
  参考文献：
  名称：

  Nikitskaja et al., Zhurnal Obshchei Khimii, 1958, vol. 28, p. 161,166; engl. Ausg. S. 161, 165

  摘要：

  DOI：

文献信息

• Co₂(CO)₈ as a Solid CO (g) Source for the Amino Carbonylation of (Hetero)aryl Halides with Highly Deactivated (Hetero)arylamines
  作者：Srinivas Cheruku、Ayyiliath M Sajith、Yatheesh Narayana、Poornima Shetty、Sandhya C Nagarakere、Kunigal S Sagar、Kumara N Manikyanally、Kanchugarkoppal Subbegowda Rangappa、Kempegowda Mantelingu

  DOI：10.1021/acs.joc.0c02999

  日期：2021.4.16

  Carbonylation of (hetero)aryl iodides/bromides with highly deactivated 2-aminopyridines using Pd–Co(CO)4 bimetallic catalysis is accomplished. The use of Co2(CO)8 as a solid CO(g) source enhanced reaction rates observed when compared to CO(g), and excellent yields highlight the versatility of the developed protocol. A wide range of electronically and sterically demanding heterocyclic amines and (hetero)aryl

  使用Pd–Co（CO）4双金属催化，可高度失活的2-氨基吡啶与（杂）芳基碘化物/溴化物进行羰基化反应。与CO（g）相比，使用Co 2（CO）8作为固体CO（g）源可提高反应速度，并且出色的收率突出了所开发方案的多功能性。用于本研究的各种电子和空间要求性的杂环胺和（杂）芳基碘化物/溴化物可产生优异的氨基羰基化产物收率。所开发的方法进一步扩展为合成锥虫布鲁西和荧光素酶抑制剂。
• [EN] BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5<br/>[FR] AMIDES BIPYRIDYLES EN TANT QUE MODULATEURS DU RÉCEPTEUR-5 MÉTABOTROPIQUE DU GLUTAMATE
  申请人：MERCK & CO INC

  公开号：WO2005079802A1

  公开（公告）日：2005-09-01

  The present invention is directed to novel amides such as those of Formula (I): (I) which are mGluR5 modulators useful in the treatment or prevention of diseases and conditions in which mGluR5 is involved, including but not limited to psychiatric and mood disorders such as schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson’s disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders, such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal, obesity and other diseases. The invention is also directed to pharmaceutical compositions comprising these compounds. This invention further provides a method of treatment of these disorders and conditions by the administration of an effective amount of these novel amides and/or compositions containing these compounds.

  本发明涉及新型酰胺，如式(I)所示的酰胺：(I)，这些酰胺是mGluR5调节剂，可用于治疗或预防涉及mGluR5的疾病和症状，包括但不限于精神疾病和情绪障碍，如精神分裂症、焦虑、抑郁、双相障碍和恐慌，以及用于治疗疼痛、帕金森病、认知功能障碍、癫痫、昼夜节律和睡眠障碍，如倒班工作引起的睡眠障碍和时差反应，药物成瘾、药物滥用、药物戒断、肥胖和其他疾病。本发明还涉及包含这些化合物的药物组合物。本发明进一步提供了通过给予这些新型酰胺和/或含有这些化合物的组合物的有效量来治疗这些疾病和症状的方法。
• Bipyridyl amides as modulators of metabotropic glutamate receptor-5
  申请人：Bonnefous Celine

  公开号：US20070149547A1

  公开（公告）日：2007-06-28

  The present invention is directed to novel amides such as those of Formula (I): (I) which are mGluR5 modulators useful in the treatment or prevention of diseases and conditions in which mGluR5 is involved, including but not limited to psychiatric and mood disorders such as schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders, such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal, obesity and other diseases. The invention is also directed to pharmaceutical compositions comprising these compounds. This invention further provides a method of treatment of these disorders and conditions by the administration of an effective amount of these novel amides and/or compositions containing these compounds.

  本发明涉及新型酰胺，例如公式（I）所示的酰胺：（I），它们是mGluR5调节剂，可用于治疗或预防包括但不限于精神和情绪障碍（如精神分裂症、焦虑、抑郁、双相障碍和惊恐）以及疼痛、帕金森病、认知功能障碍、癫痫、昼夜节律和睡眠障碍（如倒班工作引起的睡眠障碍和时差反应）、药物成瘾、药物滥用、药物戒断、肥胖症和其他疾病中涉及mGluR5的疾病和症状的治疗。本发明还涉及包含这些化合物的制药组合物。本发明还提供了通过给予这些新型酰胺和/或含有这些化合物的组合物的有效量来治疗这些疾病和症状的方法。
• DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS
  申请人：Adler Marc

  公开号：US20080176833A1

  公开（公告）日：2008-07-24

  This invention provides novel dihydropyridine derivatives of the formula I having protein tyrosine kinase inhibitory activity, to process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions.

  本发明提供了一种具有蛋白酪氨酸激酶抑制活性的新型二氢吡啶衍生物，以及其制造方法和用于治疗c-Met介导的疾病或c-Met介导的病状的用途。
• A convenient synthesis of <i>N</i>-(hetero)arylamides by the oxidative coupling of methylheteroarenes with amines
  作者：Anjali Jaiswal、Preeti、Krishna Nand Singh

  DOI：10.1039/d2ob01106a

  日期：——

  An oxidative amidation of 2-methylpyridines/2-methylbenzimidazole with amines using copper acetate and elemental sulfur in DMSO to afford various N-(hetero)arylamides has been accomplished. Mechanistic studies reveal the intermediacy of N-(pyridin-2-ylmethyl)aniline and confirm the role of DMSO as the oxygen source.

  已经完成了使用乙酸铜和元素硫在 DMSO 中将 2-甲基吡啶/2-甲基苯并咪唑与胺的氧化酰胺化，以提供各种N- (杂)芳基酰胺。机理研究揭示了N- (pyridin-2-ylmethyl)aniline 的中间体，并证实了 DMSO 作为氧源的作用。